期刊文献+

甲氨蝶呤不同给药方式治疗182例异位妊娠临床分析 被引量:5

原文传递
导出
摘要 目的观察甲氨蝶呤(MTX)不同给药方式治疗异位妊娠患者的疗效及不良反应。方法回顾分析182例异位妊娠患者的临床资料,按药物保守治疗方案不同分两组iA组(73例)给予MTX0.4mg/(kg·d),单次臀部肌注,5d为1疗程;B组(109例)用MTX1mg/kg第1、3、5、7天肌肉注射,四氢叶酸(CF)0.1mg/kg,第2、4、6、8天肌肉注射。比较MTX两种不同给药方法异位妊娠患者的疗效及不良反应。结果B组患者采用甲氨蝶呤联合四氢叶酸治疗异位妊娠的治愈率明显高于A组(X2=4.04,P〈0.05),药物不良反应低于A组(P〈0.05)。结论甲氨蝶呤联合四氢叶酸的8日疗法治疗异位妊娠患者(血B—HCG2000—5000mlU/m1)疗效确切,不良反应少。亦是特殊部位妊娠术前预处理的有较方法。
出处 《中国医师杂志》 CAS 2012年第4期561-563,共3页 Journal of Chinese Physician
  • 相关文献

参考文献6

  • 1周平.MTX单次与多次给药方式保守治疗异位妊娠比较[J].中国优生与遗传杂志,2011,19(1):68-69. 被引量:9
  • 2李伟,高丽,吴传盛.异位妊娠非手术治疗96例疗效观察[J].中国医师杂志,2008,10(9):1280-1281. 被引量:3
  • 3Hoover KW, Tao G, Kent CK, et al. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gyne-col, 2010, 115(3) :495-502.
  • 4Balci O, Ozdemir S, Mahmoud AS, et al. The efficacy of multiple- dose methotrexate treatment for unruptured tubal ectopic pregnancy and conversion rate to surgery: a study on 294 cases. Fertil Ster- ill ,2010, 93 (7) :2415-2417.
  • 5Stovall TG, Ling FW, Gray LA, et al. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstet Gyne- col, 1991,77 (5) :749-753.
  • 6Barnhart KT, Gosman G, Ashby R, et al. The medical manage- ment of ectopic pregnancy: Ameta-analysis comparing " single dose" and " multidose" regimens. Obstet Gynecol, 2003, 101 (4) :778-784.

二级参考文献6

共引文献10

同被引文献25

  • 1王逸菲.甲氨蝶呤不同给药方法治疗异位妊娠疗效观察[J].大连医科大学学报,2007,29(3):279-280. 被引量:3
  • 2李志玲.米非司酮联合氨甲喋呤治疗异位妊娠138例疗效的临床观察[J].国际医药卫生导报,2006,12(15):84-85. 被引量:4
  • 3Forscher C, Mita M, Figlin R. Targeted therapy for sarcomas[ J]. Biologics, 2014,8 : 91-105.
  • 4Meyers PA, Schwartz CL, Krailo MD, et al. Osteosareoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group[ J]. J Clin Oncol,2008,26(4) :633-638.
  • 5Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma [ J]. Curt Opin Pharmacol,2014,16C :15-23.
  • 6Rosen G, Caparros B, Huvos AG, et al. Preoperative chemothera- py for osteogenic sal"coma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preop- erative chemotherapy [ J ]. Cancer, 1982,49 (6) : 1221-1230.
  • 7Bernstein M, Kovar H, Paulussen M. Late side effects of neoadju vant chemotherapy in patients treated for osteosarcoma and Ewing sarcoma: an Italian Sacoma Group study [ J ]. J Clin Oncol (Meet- ing Abstracts), 2010, 28 Suppl 15 : 9551.
  • 8Hamad K, Tomita Y, Inoue A, et al. Evaluation of chemothera- py response in osteosarcoma with FDG-PET [ J ]. Ann Nucl Med, 2009,23 ( 1 ) :89-95.
  • 9Federman N, Bemthal N, Eilber FC, et al. The multidisciplinary management of osteosarcoma [ J ]. Curt Treat Options Oncol,2009, 10(1-2) :82-93.
  • 10Federman N, Bemthal N, Eilber FC, et al. The multidisciplinary management of osteosarcoma [ J ]. Curr Treat Options Oncol,2009, 10(1-2) :82-93.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部